NVIDIA Corp. diskutieren
NVIDIA Corp.
WKN: 918422 / Symbol: NVDA / Name: NVIDIA / Aktie / Halbleiter / Large Cap /
115,14 €
0,63 %
NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at Craig Hallum from $700.00 to $850.00. They now have a "buy" rating on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at Tigress Financial from $790.00 to $985.00. They now have a "buy" rating on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $900.00 price target on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) is now covered by analysts at CICC Research. They set an "outperform" rating and a $870.00 price target on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at Mizuho from $850.00 to $1,000.00. They now have a "buy" rating on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at Bank of America Co. from $925.00 to $1,100.00. They now have a "buy" rating on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $1,000.00 price target on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at Susquehanna from $850.00 to $1,050.00. They now have a "positive" rating on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at Wells Fargo & Company from $840.00 to $970.00. They now have an "overweight" rating on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its "overweight" rating re-affirmed by analysts at KeyCorp. They now have a $1,100.00 price target on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $875.00 to $1,000.00. They now have a "buy" rating on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $1,000.00 price target on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $850.00 to $1,100.00. They now have an "outperform" rating on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at Piper Sandler from $850.00 to $1,050.00. They now have an "overweight" rating on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at Citigroup Inc. from $820.00 to $1,030.00. They now have a "buy" rating on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $910.00 price target on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at Argus from $850.00 to $950.00. They now have a "buy" rating on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at TD Cowen from $900.00 to $1,100.00. They now have an "outperform" rating on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its price target raised by analysts at UBS Group AG from $800.00 to $1,100.00. They now have a "buy" rating on the stock.
Ratings data for NVDA provided by MarketBeat
NVIDIA Co. (NASDAQ: NVDA) had its "positive" rating re-affirmed by analysts at Susquehanna. They now have a $1,050.00 price target on the stock.
Ratings data for NVDA provided by MarketBeat
Neueste Beiträge
Stifel_Nicolaus in BioMarin Pharmaceutical Inc. diskutieren